Asia Myelodysplastic Syndrome (MDS) Registry

Bristol-Myers Squibb (BMS)

Status: Not yet enrolling

Conditions: Myelodysplastic Syndromes (MDS)

Treatments: Drug: Prescribed treatments for myelodysplastic syndromes (MDS)

Study type: Observational

Funder types: Industry

Identifiers

NCT07355478

CA056-1131

Details and patient eligibility

About

The purpose of this study is to provide a contemporary view and offer invaluable insights into the demographic profiles, clinical characteristics, treatments, and real-world outcomes of individuals with myelodysplastic syndromes (MDS) in Asia.

Enrollment: 500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Retrospective enrolment of Myelodysplastic Syndrome (MDS) participants:

• Aged at least 18 years at initial diagnosis of MDS
• Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 January 2019 and 31 December 2022; and
• Diagnosed with MDS within 100 days from the date of diagnostic bone marrow (BM) aspirate

Inclusion criteria for the prospective enrolment of MDS participants:

• Aged at least 18 years at initial diagnosis of MDS; and
• Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 October 2025 and 30 September 2026; and
• Diagnosed with MDS within 100 days from the date of diagnostic BM aspirate

Exclusion criteria

• None

Trial design

500 participants in 1 patient group

Group 1

Description:

Participants diagnosed with myelodysplastic syndromes (MDS)

Treatment:

Drug: Prescribed treatments for myelodysplastic syndromes (MDS)